Lilotomab (0-40 µg/mL; 12 days) reduces the clonogenic survival of DOHH2 and Ramos cells.Lilotomab (40 µg/mL; 18 h) induces slight apoptosis in DOHH2 cells.
Lilotomab (0-40 µg/mL; 12 days) reduces the clonogenic survival of DOHH2 and Ramos cells[1].Lilotomab (40 µg/mL; 18 h) induces slight apoptosis in DOHH2 cells[1].
Lilotomab (0.5 mg/kg; i.v.; once) inhibits tumor growth in mice[1].
References:
[1]. Malenge MM, et al. 177Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. J Nucl Med. 2020 Oct;61(10):1468-1475.